

**Enterprise P&T Meeting
Committee Meeting Minutes
February 5, 2024**

Voting Members Present

Christopher Antypas, PharmD	David Batluck, DO	Floyd (John) Brinley, MD	Kirt Caton, MD	Donald Cooper, PharmD
Tracey Davis, PharmD	Fury Fecondo, PharmD	Robert Hockmuth, MD	Emily Kryger, PharmD	Lenaye Lawyer, MD
Kelly Martin, PharmD	Michelle Murphy, PharmD	Eric Peters, PharmD	Andrew Peterson, PharmD	David Petkash, MD
Christy Skibicki, MD	Loretta Sonnier, MD	Rani Whitfield, MD		

Excused Voting Members

Michael Baer, MD	Donald Beam, MD	Rogers Elebra, PharmD	Kendra Michael, MD	Yavar Moghimi, MD
Kirby Smith, MD	Wayne Weart, PharmD			

Invited Guests Present

Christian Andreaggi, PharmD	Bethany Baird, CPhT	Linda Carreras, CPhT	Sheena Cherian, PharmD	Kathleen Clement
Mike Colvin, PharmD	Natalie Dick, CPhT	Rajneel Farley, PharmD	Amanda Hunter, PharmD	Toks Kassim, PharmD
Lisa Kazakis	Jeffrey Kreitman, PharmD	Lauren Megargell, PharmD	Melissa Megrdochian, PharmD	Christopher Meny, PharmD
Patty Oaster	Sarah Pawlak, PharmD	Victoria Pinkovsky	Jeanine Plante, PharmD	Ally Seitz, PharmD
Ruth Smith, PharmD	Luke Stadler, PharmD	Mali Thomas, CPhT	Erich Weiss, PharmD	Arlene Wiseman, PharmD

Issue	Discussion	Conclusion/Results	Action/ Person Responsible
1. Call to Order	<p>The meeting was called to order at 6:02 PM EST.</p> <p>Welcomed all external and internal participants.</p>	Informational Only	Lenaye Lawyer
2. Conflict of Interest Disclosure	No conflicts announced	Informational Only	Jeffrey Kreitman
[REDACTED]		[REDACTED]	[REDACTED]
4. Review and approval of Oct. P&T, Dec. and Jan. Proxy Minutes		<p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Robert Hockmuth</p>	Jeffrey Kreitman
5. Old Business			
[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>

	<ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] 		
<p>6. New Business</p>			
<p>Pompe Disease Agents</p>	<p>PerformRx makes the following recommendations:</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: David Batluck Second: Robert Hockmuth</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] <p>[REDACTED]</p> <p>[REDACTED]/CHC:</p> <ul style="list-style-type: none"> • Approve the newly developed Pompe Disease Agents prior authorization criteria. <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] 		
<p>Qlosi – Presbyopia Agents</p>	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: David Batluck Second: Robert Hockmuth</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] 		
[REDACTED]	<ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] 	<ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] [REDACTED] 	<ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] [REDACTED]
7. Drug Reviews			
A. Therapeutic Class			
First Generation Antihistamines	<p>PerformRx makes the following recommendations:</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Kirt Caton Second: Donald Cooper</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

█ [REDACTED]
[REDACTED]
[REDACTED] █ █ █ █ █
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]

█ [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]/CHC:

- Remove Diphenhydramine (Diphen®) 12.5 mg/5 mL oral elixir due too little to no utilization and availability of various cost-effective alternatives on the formulary.
- Remove Diphenhydramine (Alka-Seltzer Plus Allergy, Compoz, NightTime Sleep Aid, Nytol®, Rest Simply, Simply Sleep, Sleep Aid, Sleep II, Sleep Tablet, Sleep-Tabs, Sominex®) 25 mg oral tablet, gel cap, caplet due to little utilization and availability of the same strength on formulary.
- Remove Chlorpheniramine (Allergy Relief, Chlor-Trimeton Allergy, Chlorphen SR) 12 mg oral tablet due to no utilization and availability of

various cost-effective alternatives on the formulary.

[REDACTED]

■

[REDACTED]

■

[REDACTED]

■

[REDACTED]

■

[REDACTED]

■

[REDACTED]

■

[REDACTED]

	<p>[REDACTED]</p>		
Antitussives/Expectorants	<p>PerformRx makes the following recommendations:</p> <ul style="list-style-type: none">[REDACTED][REDACTED][REDACTED][REDACTED][REDACTED][REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED][REDACTED][REDACTED][REDACTED][REDACTED][REDACTED][REDACTED][REDACTED][REDACTED] <ul style="list-style-type: none">[REDACTED][REDACTED][REDACTED][REDACTED]	<p>Committee approved as recommended:</p> <p>Motion: Kirt Caton Second: Donald Cooper</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <p>[REDACTED]/CHC:</p> <ul style="list-style-type: none">Remove pseudoephedrine-codeine-guaifenesin (Tusnel C) oral syrup 30-10-100 mg/5 ml from formulary due to little to no utilization and availability of various cost-effective alternatives on the formulary.Update the quantity limit for Guaifenesin-codeine (Cheratussin AC) oral solution 100-10 mg/5 ml to 120mL per 30 days. <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED]		
<p>[REDACTED]</p>	<p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

	<p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p>		
B. Single Products			
Methergine	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]/CHC:</p> <ul style="list-style-type: none">• Recommends no changes. <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED]	<p>Committee approved as recommended:</p> <p>Motion: Kirt Caton Second: Donald Cooper</p>	No Changes

[REDACTED]

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

[REDACTED]/CHC:

- Add Casgevy to Tier 4 of the formulary with a prior authorization requirement.
- Update the Gene Therapy for Regular Red Blood Cell (RBC) Transfusion Dependent Beta-Thalassemia prior authorization criteria.
 - Add criteria to exclude repeat use or use after one agent fails to align with available data.
 - Add age restriction per label as Casgevy is only approved for ages 12 and up while Zynteglo has no age restriction.

- Remove requirement to show that HSCT was not accessible, as preference is based on a variety of factors including age and long-term immunosuppression.
- Prefer use of Casgevy over Zynteglo.
- Approve the newly developed Gene Therapy for Sickle Cell Disease prior authorization criteria.

■ [REDACTED]

- [REDACTED]
[REDACTED]

- [REDACTED]
[REDACTED]
[REDACTED]

- [REDACTED]
[REDACTED]

- [REDACTED]
[REDACTED]
[REDACTED]

- [REDACTED]
[REDACTED]
[REDACTED]

- [REDACTED]

- [REDACTED]

- [REDACTED]

	<ul style="list-style-type: none">■ [REDACTED]		
Lyfgenia with PA Criteria	<p>PerformRx makes the following recommendations:</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]	<p>Committee approved as recommended:</p> <p>Motion: Kirt Caton Second: Donald Cooper</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED] <p>█ [REDACTED] /CHC:</p> <ul style="list-style-type: none">• Add Lyfgenia to Tier 4 of the formulary with a prior authorization requirement.• Approve the newly developed Gene Therapy for Sickle Cell Disease prior authorization criteria. <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED]		
█ [REDACTED]	█ [REDACTED]	█ [REDACTED]	█ [REDACTED]

	<p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED][REDACTED][REDACTED][REDACTED][REDACTED][REDACTED][REDACTED][REDACTED][REDACTED]		
<p>Sohonos with PA Criteria</p>	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED]	<p>Committee approved as recommended:</p> <p>Motion: Kirt Caton Second: Donald Cooper</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

[REDACTED]/CHC:

- Add Rivfloza to Tier 4 of the formulary with a prior authorization requirement.
- Update the Oxlumo (lumasiran) prior authorization criteria to include Rivfloza
 - Update the title from Oxlumo to Primary Hyperoxaluria Agents to account for additional agent.
 - Update the drug list and criteria for the newly approved Rivfloza product.

- [REDACTED]**
- [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]

	<ul style="list-style-type: none">■ [REDACTED]		
Zurzuvae with PA Criteria	<p>PerformRx makes the following recommendations:</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]	<p>Committee approved as recommended:</p> <p>Motion: Kirt Caton Second: Donald Cooper</p> <p>Comments and discussion:</p> <p>David Petkash comment: Psychiatrist should be approving the request.</p> <p>Loretta Sonnier comment: Discussion on how to manage redosing after six months. No data on redosing and the drug is limited to a one-time treatment.</p> <p>Jeff Kreitman comment: From operational standpoint the request will not be approved based on the criteria. Appeal request will be evaluated.</p> <p>Lauren Megargell comment:</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

■ [REDACTED]
[REDACTED]

■ [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

■ [REDACTED]
■ [REDACTED]
[REDACTED]

■ [REDACTED]
[REDACTED]
■ [REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

■ [REDACTED]
[REDACTED]

■ [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]

■ [REDACTED]
[REDACTED]
■ [REDACTED]
[REDACTED]

[REDACTED] /CHC:

- Add Zurzuvae to Tier 3 of the formulary with a prior authorization requirement.
- Update the Zulresso prior authorization criteria to include Zurzuvae.
 - Update the title from Zulresso to Agents for the Treatment of Postpartum Depression to account for multiple agents addressed in the policy.
 - Add Zurzuvae to the drug list.
 - Update age restrictions to align with package inserts for both agents.
 - Update coverage duration to allow for a 14-day course of Zurzuvae.
 - Update diagnosis requirement to severe postpartum depression validated by a screening tool and where the patient cannot wait 4-6 weeks for the standard of care antidepressants to take effect.
 - Patient will be no more than 6 months postpartum.
 - Add attesting for Zurzuvae requests that the patient was advised not to drive after each dose to align with black box warning.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

- Pombiliti
- Trientine
- Zemaira

Add to the Specialty Tier 4 with PA requirement for [REDACTED]/CHC:

- Fabhalta
- Kepivance
- Loqtorzi
- Ogsiveo

[REDACTED]

[REDACTED]

- [REDACTED]

[REDACTED]

[REDACTED]

- [REDACTED]

- [REDACTED]

- [REDACTED]

[REDACTED]

[REDACTED]

- [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

- [REDACTED]

- [REDACTED]






- [REDACTED]

- [REDACTED]

- [REDACTED]

	<p>Remain non-formulary/non-preferred for ██████████/CHC ██████████</p> <ul style="list-style-type: none"> • Adzynma • Immphentiv • Jylamvo • Meropenem • Pokonza • Rezipres <p>████████████████████</p> <ul style="list-style-type: none"> █ █████ █ █████ █ █████ <p>██</p> <p>██████████</p> <ul style="list-style-type: none"> █ ██████████ 		
<p>9. Prior Authorization Criteria Review</p>			
<p>A. Prior Authorization Annual Criteria</p>			
<p>██████████.CHC Compound Products</p>	<p>PerformRx makes the following recommendations:</p> <p>██████████/CHC:</p> <ul style="list-style-type: none"> • Decrease the dollar limit to \$250 for compounded products that need a prior authorization review. 	<p>Committee approved as recommended:</p> <p>Motion: David Batluck Second: Andrew Peterson</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>
<p>██</p>	<p>██</p> <p>██</p>	<p>██</p> <p>██</p>	

	<p>[REDACTED]</p>		
Glycopyrrolate	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]/CHC:</p> <ul style="list-style-type: none">Remove Dartisla ODT from the drug list and criteria as it was discontinued. <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: David Batluck Second: Andrew Peterson</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>
<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>

			
Relyvrio	PerformRx makes the following recommendations: 	Committee approved as recommended: Motion: David Batluck Second: Andrew Peterson	PerformRx will update the criteria and formulary/PDL with any changes

	<p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <p>[REDACTED]/CHC:</p> <ul style="list-style-type: none">Update the example listed for a positive clinical response in relation to re-authorization. <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED]		
<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>

<p>[REDACTED]</p>	<p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] 	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>
<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] 	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>
<p>B. Prior Authorization Criteria Annual Review without Clinical Changes:</p>			
<p>Adrenal Enzyme Inhibitors for Cushing's Disease (Isturisa)</p>	<p>PerformRx makes the following recommendations:</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: David Batluck Second: Andrew Peterson</p>	<p>No Changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED] /CHC:</p> <ul style="list-style-type: none">• Approve the Adrenal Enzyme Inhibitors for Cushing's Disease prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED]		
--	---	--	--

	<p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]/CHC:</p> <ul style="list-style-type: none"> • Approve the Benlysta (belimumab) prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] 		
Blincyto	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: David Batluck Second: Andrew Peterson</p>	<p>No Changes</p>

	<ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED] <p>█ [REDACTED] /CHC:</p> <ul style="list-style-type: none">• Approve the Blincyto prior authorization criteria with no clinical changes. <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED]		
<p>█ [REDACTED]</p>	<p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p>	<p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED]</p>	<p>█ [REDACTED]</p>

	<ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p>		
Corlanor	<p>PerformRx makes the following recommendations:</p> <ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: David Batluck Second: Andrew Peterson</p>	<p>No Changes</p>

	<ul style="list-style-type: none">█ [REDACTED] <p>█ [REDACTED]</p> <p>█ [REDACTED] /CHC:</p> <ul style="list-style-type: none">• Approve the Corlanor prior authorization criteria with no clinical changes. <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]		
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators	<p>PerformRx makes the following recommendations:</p> <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]	<p>Committee approved as recommended:</p> <p>Motion: David Batluck Second: Andrew Peterson</p>	<p>No Changes</p>

	<ul style="list-style-type: none">█ [REDACTED] [REDACTED] [REDACTED] <p>█/CHC:</p> <ul style="list-style-type: none">• Approve the Dojolvi prior authorization criteria with no clinical changes. <p>█</p> <ul style="list-style-type: none">█ [REDACTED] [REDACTED] [REDACTED]		
<p>█ █ █</p>	<p>█ █</p> <ul style="list-style-type: none">█ [REDACTED] [REDACTED] [REDACTED] [REDACTED] <p>█</p> <ul style="list-style-type: none">█ [REDACTED] [REDACTED] [REDACTED] [REDACTED] <p>█</p> <ul style="list-style-type: none">█ [REDACTED] [REDACTED] [REDACTED] [REDACTED]	<p>█ █</p> <p>█ █</p>	<p>█</p>

	<p>█ █ █ █ █ █</p> <p>█ █ █ █ █ █</p>		
<p>Enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD)</p>	<p>PerformRx makes the following recommendations:</p> <p>█ █ █ █ █ █</p> <p>█ █ █ █ █ █</p> <p>█ █ █ █ █ █</p> <p>█ █ █ █ █ █</p>	<p>Committee approved as recommended:</p> <p>Motion: David Batluck Second: Andrew Peterson</p>	<p>No Changes</p>

	<ul style="list-style-type: none">█ [REDACTED]		
<p>Mucopolysaccharidosis IV (Maroteaux-Lamy Syndrome) Agents - Naglazyme</p>	<p>PerformRx makes the following recommendations:</p> <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED] <p>█ [REDACTED] /CHC:</p> <ul style="list-style-type: none">• Approve the Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome) Agents	<p>Committee approved as recommended:</p> <p>Motion: David Batluck Second: Andrew Peterson</p>	<p>No Changes</p>

	<p>prior authorization criteria with no clinical changes.</p> <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED]		
[REDACTED]	<p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	[REDACTED]
[REDACTED]	<p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p>	[REDACTED]

Transthyretin-mediated
Amyloidosis Agents

PerformRx makes the following
recommendations:

[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

- [REDACTED]/CHC:
- Update the Transthyretin-mediated Amyloidosis Agents prior authorization criteria with no clinical changes.

Committee approved as
recommended:

Motion: David Batluck
Second: Andrew Peterson

PerformRx will
update the criteria
and formulary/PDL
with any changes

	<ul style="list-style-type: none">• Approve the Tzield (teplizumab-mzwv) prior authorization criteria with no clinical changes.		
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

- Multi-Action Relief Drops 15ml
- Lubricating Gel Drops 10ml
- Lubricant Eye Drops 10ml (Twin Pack)
- Lubricant Gel Drops 15 ML
- Lubricant Eye Drops 15ml (Twin Pack)
- Eye Irritation Relief 15 ml
- Dry Eye Relief 10 ml
- Dry Eye Relief 15 ml
- Lubricant Eye Drops 15 ML (Single Pack)
- Lubricant Eye Drops 15 ML (Twin Pack)
- Lubricant Eye Drops 10ml
- Lubricant Eye Drop 10ml (Triple Pack)
- Lubricant Eye Drops 15ML (Single Pack)
- Lubricant Eye Drops 15 ML (Twin Pack)
- Lubricant Gel Drops 15 ml (Single Pack)
- Lubricant Gel Drops 15 ml (Twin Pack)
- Multi Action Relief Drops 15ml
- Mild Moderate Lubricating Eye Drops 15ml
- Lubricant Gel Drops 10ml
- Lubricant Eye Drops 10ml (Single Pack)
- Lubricant Eye Drops 10ml (Twin Pack)
- Dry Eye Relief 15ml (Twin Pack)
- Equate Hydration Pf Lubricant Eye Drops 10ml

The Harvard Drug Group LLC dba Major
Pharmaceuticals and Rugby Laboratories
Date: 11/29/2023

Reason:

Non-Sterility: FDA found insanitary
conditions and positive bacterial test results
from environmental sampling at the
manufacturing facility.

- Polyvinyl Alcohol 1.4% Lubricating
Eye Drops
- Lubricating Tears Eye Drops
(Dextran/Hypromellose)

Cardinal Health Inc
Date: 11/29/2023

Reason:

Non-Sterility: FDA found insanitary
conditions and positive bacterial test results
from environmental sampling at the
manufacturing facility.

- LEADER brand Eye Irritation Relief
(Polyvinyl alcohol 0.5%, Povidone
0.6%, Tetrahydrozoline Hydrochloride
0.05%)
- LEADER brand Dry Eye Relief
(Carboxymethylcellulose Sodium, 1%)
- LEADER brand Lubricant Eye Drops
(Carboxymethylcellulose Sodium,
0.5%)
- LEADER brand Lubricant Eye Drops
(Carboxymethylcellulose Sodium,
0.5%)

	<ul style="list-style-type: none"> • LEADER brand Dry Eye Relief (Polyethylene Glycol 400, 0.4% Propylene Glycol, 0.3%) • LEADER brand Lubricant Eye Drops (Propylene Glycol, 0.6%) 		
11. Adjournment	The meeting adjourned at 7:07 PM EST		Lenaye Lawyer
	The next meeting April 29th, 2024 6:00 PM- 8:00		

Jeffrey Phillip Pham

Date

5/23/24

Item	Recommendation	Vote Results	Action/ Person Responsible
[REDACTED]	<ul style="list-style-type: none"> [REDACTED] 	[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]	[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]
[REDACTED]	<ul style="list-style-type: none"> [REDACTED] 	[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]	[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]
COVID-19 Tests QL	<ul style="list-style-type: none"> Lowering the QL from 8 down to 4 per month 	Total Sent – 25 Total Responses – 18 Approved – 18 Rejected – 0 Excused – 7 End: 4/2/2024	PerformRx will implement per the outcome of the committee vote. The vote has been approved with 14 approvals and no rejections received.
Dose Rounding Limit Exception Criteria	<ul style="list-style-type: none"> Language updates for clarity 	Total Sent – 25 Total Responses – 18 Approved – 18 Rejected – 0 Excused – 7 End: 4/2/2024	PerformRx will implement per the outcome of the committee vote. The vote has been approved with 14 approvals and no rejections received.
[REDACTED]/CHC Mifepristone	<ul style="list-style-type: none"> Adding to the formulary for Pennsylvania per state requirements 	Total Sent – 25 Total Responses – 18 Approved – 17	PerformRx will implement per the outcome of the committee vote.

Item	Recommendation	Vote Results	Action/ Person Responsible
		Rejected – 1 Excused – 7 End: 4/2/2024	The vote has been approved with 14 approvals and 1 rejection received.



Jeff Kreitman, Chair

4/2/2024

Date